Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
licaminlimab · 2 trials · 2 indications
| Arm | Type | Description |
|---|---|---|
| licaminlimab | EXPERIMENTAL | 60 mg/mL licaminlimab ophthalmic solution |
| Vehicle | PLACEBO_COMPARATOR | Vehicle of licaminlimab ophthalmic solution |
| Name | Type | Description |
|---|---|---|
| Artificial Tear Run-in | OTHER | Artificial tear eye drop run-in three times daily (TID) for approximately 14 days. |
| licaminlimab | DRUG | Licaminlimab eye drops three times daily (TID) for 29 days. |
| Vehicle of licaminlimab | OTHER | Inert ophthalmic solution vehicle of licaminlimab, three times daily (TID) for 29 days. |
| vehicle of OCS-02 | OTHER | inert ophthalmic solution vehicle of OCS-02 Subjects will be randomized to receive vehicle eye drops three times daily (TID) for 6 weeks. |
| Artificial tears | OTHER | Subjects who quality after an initial screening were entered into a run-in phase where they received artificial tears to use three times daily (TID) for approximately 14 days. |
Key Inclusion Criteria: * Physician diagnosis of Dry Eye Disease in the past 6 months * Use of over-the-counter tears * Must agree to genotype testing Key Exclusion Criteria: \- Have a history or presence of any disorder or condition that may, in the opinion of the Investigator, likely interfere ...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| AbbVie, Inc. | ABBV | 2 | PHASE3 | ABBV-444, REFRESH OPTIVE UD |
| Vanda Pharmaceuticals Inc. | VNDA | 1 | PHASE2 | VSJ-110 |
| Oculis Holding AG | OCS | 1 | PHASE2 | licaminlimab |
| Alcon AG | ALC | 1 | N/A | Undisclosed |
| Harrow, Inc. | HROW | 1 | - | Undisclosed |
Licaminlimab is an investigational small molecule being developed for the treatment of Dry Eye Disease (DED). It is administered as an ophthalmic solution and is currently in Phase 2 clinical development. The drug is not yet approved by regulatory authorities and remains under investigation for this condition.
Licaminlimab targets TNFα, a cytokine involved in inflammation. By modulating this target, the drug aims to address inflammatory components of Dry Eye Disease. It is classified as an antibody (-mab) modality, though it is described as a small molecule in development for ophthalmic use.
Licaminlimab is being developed by Oculis Holding AG, a biopharmaceutical company focused on ophthalmology. The company's stock trades under the ticker OCS. Oculis is conducting clinical trials to evaluate the safety and efficacy of licaminlimab for Dry Eye Disease.
Licaminlimab is in Phase 2 clinical development. It is an investigational drug and has not received FDA approval. The development program includes both completed and ongoing Phase 2 trials evaluating the drug for Dry Eye Disease, with one trial currently recruiting participants.
Licaminlimab has two Phase 2 clinical trials. NCT07548632 is a recruiting study evaluating licaminlimab for Dry Eye Disease in the United States, with an enrollment of 160 participants. NCT05896670 is a completed study assessing the safety and efficacy of licaminlimab ophthalmic solution for Dry Eye Disease, with 122 participants.
Licaminlimab is a distinct investigational drug targeting TNFα for Dry Eye Disease. No alternative names for licaminlimab have been reported. It is being studied as an ophthalmic solution and is not yet approved, distinguishing it from marketed therapies for this condition.